St. Jude Study Shows Cell-Free DNA Can Predict Infections in Leukemia Patients — St. Jude Children's Research Hospital, Inc.

Event summary

St. Jude researchers found that microbial cell-free DNA sequencing (mcfDNA-Seq) can predict bloodstream infections in children with high-risk leukemia up to three days before symptoms appear.
The study, published in The Lancet Microbe on March 2, 2026, analyzed daily plasma samples from 158 pediatric patients.
mcfDNA-Seq accurately identified infection-causing pathogens in over half of the cases and ruled out infection in 93.8% of healthy or uninfected samples.
The technology could enable preemptive treatment, potentially reducing severe complications and improving outcomes for immunocompromised children.

The big picture

St. Jude's breakthrough in predictive diagnostics aligns with the growing trend of leveraging genomic technologies to improve patient outcomes in high-risk populations. The ability to detect infections before symptoms manifest could significantly reduce mortality rates and healthcare costs associated with bloodstream infections in immunocompromised children. This study positions St. Jude at the forefront of innovative infection management strategies, potentially influencing broader adoption of cell-free DNA sequencing in clinical settings.

What we're watching

Clinical Integration: How St. Jude will incorporate mcfDNA-Seq into treatment protocols to guide preemptive interventions.
Regulatory Approval: The pace at which mcfDNA-Seq gains regulatory clearance for routine clinical use in high-risk pediatric populations.
Commercialization Path: Whether St. Jude will license the technology or develop it further for broader applications in infection prediction.